2025 | 2024 | ||
Notes | £’m | £’m | |
Revenue | 3 | ||
Adjusted Group operating profit | |||
Net IAS 41 valuation movement in biological assets | 15 | ( | |
Amortisation of intangible assets | 10 | ( | ( |
Impairment of intangible assets | 10 | ( | ( |
Group operating profit | 4 | ||
Finance costs | 6 | ( | ( |
Share of net profit of joint venture | 14 | ||
Profit before tax | |||
Taxation | 7 | ( | ( |
Profit for the year | |||
Earnings per share | |||
On profit for the year: | |||
Basic earnings per share | 9 | ||
Diluted earnings per share | 9 |
2025 | 2024 | ||
Notes | £’m | £’m | |
Profit for the year | |||
Other comprehensive income/(expense) | |||
Other comprehensive income/(expense) to be reclassified to profit or loss in subsequent periods: | |||
Cash flow hedges | |||
Gains/(losses) arising in the year | 20 | ( | |
Reclassification adjustments for gains/(losses) included in the income statement | 20 | ( | |
Income tax effect | 7 | ( | |
Net other comprehensive income/(expense) to be reclassified to profit or loss in subsequent periods | ( | ||
Other comprehensive expense not to be reclassified to profit or loss in subsequent periods: | |||
Actuarial losses on defined benefit pension scheme | 26 | ( | |
Income tax effect | 7 | ||
Net other comprehensive expense not to be reclassified to profit or loss in subsequent periods | ( | ||
Other comprehensive income/(expense) | ( | ||
Total comprehensive income |
2025 | 2024 | ||
Notes | £’m | £’m | |
Non-current assets | |||
Financial asset investment | 13 | ||
Investment in joint venture | 14 | ||
Intangible assets | 10 | ||
Defined benefit pension scheme surplus | 26 | ||
Property, plant and equipment | 11 | ||
Right-of-use assets | 12 | ||
Biological assets | 15 | ||
Total non-current assets | |||
Current assets | |||
Biological assets | 15 | ||
Inventories | 16 | ||
Trade and other receivables | 17 | ||
Other financial assets | 18 | ||
Income tax receivable | |||
Cash and short-term deposits | 27 | ||
Total current assets | |||
Total assets | |||
Current liabilities | |||
Trade and other payables | 19 | ( | ( |
Other financial liabilities | 20 | ( | ( |
Lease liabilities | 12 | ( | ( |
Provisions | 21 | ( | ( |
Total current liabilities | ( | ( | |
Non-current liabilities | |||
Other payables | 19 | ( | ( |
Other financial liabilities | 20 | ( | ( |
Lease liabilities | 12 | ( | ( |
Deferred tax liabilities | 7 | ( | ( |
Provisions | 21 | ( | ( |
Total non-current liabilities | ( | ( | |
Total liabilities | ( | ( | |
Net assets | |||
Equity | |||
Called-up share capital | 23 | ||
Share premium account | |||
Share-based payments | 25 | ||
Shares held in trust | 24 | ( | ( |
Hedging reserve | ( | ||
Retained earnings | |||
Total equity attributable to owners of the Parent |
2025 | 2024 | ||
Notes | £’m | £’m | |
Operating activities | |||
Profit for the year | |||
Adjustments to reconcile Group profit for the year to net cash inflows from operating activities: | |||
Income tax expense | 7 | ||
Net finance costs | 6 | ||
Loss on sale of property, plant and equipment | |||
Loss on disposal of right-of-use assets asset | |||
Depreciation of property, plant and equipment | 11 | ||
Depreciation of right-of-use assets | 12 | ||
Amortisation of intangible assets | 10 | ||
Impairment of intangible assets | 10 | ||
Share-based payments | |||
Share of joint venture | ( | ( | |
Release of Government grants | ( | ( | |
Net IAS41 valuation movement on biological assets | 15 | ( | |
Increase in biological assets | ( | ( | |
(Increase)/decrease in inventories | ( | ||
Increase in trade and other receivables | ( | ( | |
Increase in trade and other payables | |||
Cash generated from operations | |||
Tax paid | ( | ( | |
Net cash inflow from operating activities | |||
Cash flow from investing activities | |||
Acquisition of subsidiaries, net of cash acquired | 13 | ( | ( |
Distribution received from joint venture | 14 | ||
Payment of property, plant and equipment acquired on acquisition | 13 | ( | |
Purchase of financial asset investment | 13 | ( | |
Purchase of property, plant and equipment | ( | ( | |
Proceeds from the sale of property, plant and equipment | |||
Net cash used in investing activities | ( | ( | |
Cash flow from financing activities | |||
Interest paid | ( | ( | |
Proceeds from issue of share capital | |||
Own shares purchased | 24 | ( | ( |
Proceeds/(repayments) from borrowings | ( | ||
Repayment of borrowings acquired | 13 | ( | |
Dividends paid | 8 | ( | ( |
Payment of lease capital | ( | ( | |
Payment of lease interest | 12 | ( | ( |
Net cash outflow from financing activities | ( | ( | |
Net (decrease)/increase in cash and cash equivalents | 27 | ( | |
Cash and cash equivalents at beginning of year | 27 | ||
Cash and cash equivalents at end of year | 27 |
Share | Share-based | Shares held | Hedging | ||||
Share capital | premium | payments | in trust | reserve | Retained | Total | |
Note (a) | Note (b) | Note (c) | Note (d) | Note (e) | earnings | equity | |
£’m | £’m | £’m | £’m | £’m | £’m | £’m | |
At 25 March 2023 | |||||||
Profit for the year | |||||||
Other comprehensive expense | ( | ( | |||||
Total comprehensive income/(expense) | ( | ||||||
Share-based payments | |||||||
Shares acquired by Employee Benefit Trust | ( | ( | |||||
Exercise, lapse or forfeit of share-based payments | ( | ||||||
Share options exercised | |||||||
Dividends | ( | ( | |||||
Deferred tax related to changes in equity | |||||||
Current tax related to changes in equity | |||||||
At 30 March 2024 | ( | ( | |||||
Profit for the year | |||||||
Other comprehensive income/(expense) | ( | ||||||
Total comprehensive income | |||||||
Share-based payments | |||||||
Shares acquired by Employee Benefit Trust | ( | ( | |||||
Transfer to retained earnings on grant of shares to beneficiaries | |||||||
of the Employee Benefit Trust | ( | ||||||
Exercise, lapse or forfeit of share-based payments | ( | ||||||
Share options exercised | |||||||
Dividends | ( | ( | |||||
Deferred tax related to changes in equity | |||||||
Current tax related to changes in equity | |||||||
At | ( |
Significant estimates and assumptions: | |
Goodwill | Note 10 – intangible assets. |
The carrying value of goodwill is tested annually for impairment. For each cash-generating unit (‘CGU’) the recoverable amount | |
is determined as the value-in-use. | |
For value-in-use models, the sensitivity of the assumptions applied in the model, including the estimated risk-adjusted future pre-tax | |
cash flows, which are derived from Board-approved budgets, and the pre-tax discount rate applied, which represents the Group’s | |
pre-tax weighted average cost of capital (‘WACC’), carries most of the estimation uncertainty. | |
Refer to Note 10 for the sensitivity analysis of key assumptions on the value-in-use calculations and impairment outcomes. | |
Biological | Note 15 – growth rate assumptions used in the fair value model. |
assets | Pigs |
The key estimate in determining the fair value of pigs is market prices. | |
Quoted (unadjusted) prices in an active market are no longer available for sucklers and weaners. The Group’s valuation model for | |
sucklers and weaners is, therefore, a function of the UK Standard Pig Price (‘SPP’) for finished pigs since historic data suggests that | |
prices for sucklers, weaners and finished pigs were strongly correlated. The derived prices for sucklers and weaners are then adjusted | |
to reflect the growth of the pigs through a straight-line interpolation based on age, to provide a value for the pigs at a particular stage | |
of growth. As suckler and weaner prices are no longer observable in the market, management concludes these prices fall within Level | |
3 of the fair value hierarchy. Refer to Note 22 for key assumptions about unobservable inputs, their relationship to fair value and | |
sensitivity analysis. | |
The Group’s valuation model for finished pigs utilises quoted (unadjusted) prices in an active market. The prices are then adjusted | |
to reflect the growth of the animals through straight-line interpolation between prices to provide a value for the finished pigs at | |
a particular stage of growth. As the estimated weaner price used in the straight-line interpolation for finished pigs is no longer | |
observable in the market, management concludes these prices fall within Level 3 of the fair value hierarchy. | |
Poultry | |
Estimates in determining the fair value of poultry relate to market prices. | |
The valuation for broiler birds uses recent transaction prices at various stages of development. The prices are then adjusted to reflect | |
the growth of the birds through interpolation between the transaction prices. Interpolation is used as an approximate growth rate. | |
Estimates relating to biological assets are not expected to have a material impact on the next 12 months. | |
Share-based | Note 25 – measurement of share-based payments. |
payments | The fair value of share-based payments is estimated using inputs including expected share price volatility, the expected life of |
the options and the number of awards that will ultimately vest. This estimate is not expected to have a material impact on the | |
next 12 months. | |
Pensions | Note 26 – pension scheme actuarial assumptions. |
The valuation of the defined benefit pension scheme liability is determined using assumptions including mortality, discount rates and | |
inflation. | |
Significant judgements: | |
Goodwill | Note 10 – intangible assets |
The level at which goodwill is tested for impairment involves judgement. Management assess the nature of the individual businesses | |
as well as the internal information presented to the Board to determine the level at which goodwill is monitored for the purpose | |
of goodwill impairment testing. Changes to this assessment could impact the value-in-use calculation, affecting the conclusion | |
of whether assets’ carrying amounts are recoverable. Following a review completed in the prior year, the goodwill impairment | |
assessment for the Fresh Pork and Livestock CGUs is completed on a combined basis consistent to how it is monitored by the | |
management. The resulting change does not impact management’s assessment of goodwill impairment considerations in | |
current period or prior years. | |
Share-based | Note 25 – measurement of share-based payments. |
payments | The selection of valuation models requires the use of management’s judgement. The fair value of share-based payments is estimated |
as at the date of grant using a Black–Scholes option pricing model or a stochastic option pricing model. | |
Pensions | Note 26 – pension scheme actuarial assumptions. |
The Group has the right to recover any remaining surplus on the winding up of the pension scheme. The expected method of recovery | |
of the recognised pensions surplus is through reduction in future contributions or recovery of any remaining surplus through a refund. | |
Management have applied judgement on the scheme rules to conclude the Group has the right to a refund. The rules state that | |
any surplus remaining in the hands of the Trustees may, at the discretion of the Trustees, be used to increase the pensions | |
payable or contingently payable to Members and/or their Dependents. Any surplus remaining in the hands of the Trustees after | |
making such provision (if any) shall be paid to the Employers. Management have formed the judgement, based on paragraph BC10 | |
of IFRIC 14, that the right to the surplus is not affected by future acts that could change the amount of surplus that could ultimately | |
be recovered. The Trustees ability to use discretion and choose to grant benefit improvements (thus reducing the surplus) has, | |
therefore, not been anticipated and does not remove the Company’s unconditional right to the surplus. | |
Alternative | Note 31 – alternative performance measures. |
performance | Management apply judgement to identify the significant non-cash items to exclude when calculating adjusted performance measures. |
measures | The Board believe alternative measures are useful as they exclude volatile, one-off and non-cash items. |
2025 | 2024 | |||||
£’m | Food | Other | Total | Food | Other | Total |
Revenue | 2,686.6 | 36.7 | 2,723.3 | 2,573.9 | 25.4 | 2,599.3 |
Adjusted operating profit/(loss) | 210.3 | (3.4) | 206.9 | 192.5 | ( 7.4) | 185.1 |
Finance costs | (8.0) | (1.2) | (9.2) | (8.9) | – | (8.9) |
Share of net profit of joint venture | 0.2 | – | 0.2 | 0.4 | – | 0.4 |
Adjusted profit/(loss) before tax | 202.5 | (4.6) | 197.9 | 184.0 | ( 7. 4) | 176.6 |
Assets | 1,503.0 | 28.2 | 1,531.2 | 1,355.0 | 29.0 | 1,384.0 |
Liabilities | (510.7) | (32.6) | (543.3) | (446.2) | (26.3) | (472.5) |
Net assets/(liabilities) | 992.3 | (4.4) | 987.9 | 908.8 | 2.7 | 911.5 |
Depreciation | 84.0 | 2.3 | 86.3 | 79.0 | 2.7 | 81.7 |
Property, plant and equipment and right-of-use asset additions | 150.0 | 2.7 | 152.7 | 120.0 | 6.0 | 126.0 |
2025 | 2024 | |
£’m | £’m | |
UK | 2,651.2 | 2,543.7 |
Continental Europe | 26.2 | 24.9 |
Rest of World | 45.9 | 30.7 |
2,723.3 | 2,599.3 |
2025 | 2024 | |
£’m | £’m | |
Cost of sales excluding net IAS 41 valuation movement on biological assets | 2,303.4 | 2,224.6 |
Net IAS 41 valuation movement on biological assets* | 11.1 | (2.2) |
Cost of sales | 2,314.5 | 2,222.4 |
Gross profit | 408.8 | 376.9 |
Selling and distribution costs | 112.8 | 100.0 |
Administrative expenses excluding impairment and amortisation of intangible assets | 100.2 | 95.3 |
Impairment of intangible assets | 1.6 | 15.4 |
Amortisation of intangible assets | 3.6 | 5.0 |
Administrative expenses | 105.4 | 115.7 |
Other operating income | – | (5.7) |
Total operating costs | 2,532.7 | 2,432.4 |
2025 | 2024 | |
£’m | £’m | |
Staff costs: | ||
Wages and salaries | 433.2 | 388.4 |
Social security costs | 44.7 | 35.8 |
Other pension costs | 11.1 | 9.7 |
489.0 | 433.9 |
2025 | 2024 | ||
Number | Number | ||
Production | 10,800 | 9,720 | |
Selling and distribution | 624 | 490 | |
Administration | 844 | 828 | |
11,03 | 8 |
2025 | 2024 | |
£’m | £’m | |
Directors’ remuneration | 8.2 | 7. 2 |
Aggregate gains made by Directors on exercise of share options | 5.7 | 2.8 |
Number of Directors receiving pension contributions under money purchase schemes | 2 | 1 |
2025 | 2024 | |
£’m | £’m | |
Finance costs: | ||
Bank interest paid and similar charges | 3.2 | 5.3 |
Total interest expense for financial liabilities not at fair value through profit or loss | 3.2 | 5.3 |
Lease interest | 6.0 | 3.6 |
Total finance costs | 9.2 | 8.9 |
2025 | 2024 | |
£’m | £’m | |
Current income tax: | ||
UK corporation tax on profit for the year | 41.7 | 3 7.8 |
Adjustments in respect of prior years | 0.6 | 0.7 |
Total current tax | 42.3 | 38.5 |
Deferred tax: | ||
Origination and reversal of temporary differences | 6.2 | 7.5 |
Adjustments in respect of prior years | (1.2) | (0.7) |
Total deferred tax | 5.0 | 6.8 |
Tax on profit | 47. 3 | 45.3 |
2025 | 2024 | |
£’m | £’m | |
Recognised in Group Statement of Comprehensive Income | ||
Deferred tax on revaluation of cash flow hedges | 0.1 | (0.1) |
Deferred tax on actuarial losses on defined benefit pension scheme | 0.1 | 0.1 |
Corporation tax credit on defined benefit pension scheme | (0.1) | (0.1) |
0.1 | (0.1) | |
Recognised in Group Statement of Changes in Equity | ||
Deferred tax credit on share-based payments | (2.7) | (1.4) |
Corporation tax credit on share options exercised | (1.0) | (0.5) |
(3.7) | (1.9) | |
Total tax credit recognised directly in equity | (3.6) | (2.0) |
2025 | 2024 | |
£’m | £’m | |
Profit before tax | 181.6 | 158.4 |
Profit multiplied by standard rate of corporation tax in the UK of 25 per cent (2024: 25 per cent) | 45.4 | 39.6 |
Effect of: | ||
Expenses which are not deductible for tax purposes | 2.5 | 1.9 |
Goodwill impairment | – | 3.8 |
Adjustments in respect of prior years | (0.6) | – |
Total tax charge for the year | 47.3 | 45.3 |
2025 | 2024 | |
£’m | £’m | |
Deferred tax liability in the balance sheet | ||
Accelerated capital allowances | 41.1 | 29.2 |
Business combinations | 3.5 | 3.6 |
Losses | (0.5) | (0.6) |
Biological assets | (3.2) | (0.1) |
Right-of-use asset | 26.9 | 18.9 |
Right-of-use liability | (28.5) | (19.9) |
Other temporary differences | – | 0.2 |
Share-based payments | (8.4) | (5.2) |
Deferred tax on defined benefit pension scheme | (0.1) | (0.2) |
Intangible assets | 1.2 | 2.5 |
Deferred tax liability | 32.0 | 28.4 |
2025 | 2024 | |
£’m | £’m | |
Deferred tax liability in the balance sheet | ||
At 30 March 2024 | 28.4 | 20.7 |
Recognised in income statement | 6.2 | 7.5 |
Prior year adjustments recognised in income statement | (1.2) | (0.7) |
Acquired on acquisitions in the year | 1.1 | 2.3 |
Recognised in statement of comprehensive income | 0.2 | – |
Recognised in statement of changes in equity | (2.7) | (1.4) |
At 29 March 2025 | 32.0 | 28.4 |
2025 | 2024 | |
£’m | £’m | |
Deferred tax liability in the income statement | ||
Accelerated capital allowances | 10.5 | 8.2 |
Business combinations | (0.1) | (0.1) |
Losses | 0.1 | 0.9 |
Biological assets | (2.8) | 0.6 |
Right-of-use asset | 8.0 | 2.9 |
Right-of-use liability | (8.6) | (3.3) |
Other temporary differences | (0.3) | 0.1 |
Share-based payments | (0.5) | (1.2) |
Intangible assets | (1.3) | (1.3) |
Deferred tax liability | 5.0 | 6.8 |
2025 | 2024 | |
£’m | £’m | |
Declared and paid during the year: | ||
Final dividend for 2024 – | 36.1 | 31.7 |
Interim dividend for 2025 – | 13.4 | 12.2 |
Dividends paid | 49.5 | 43.9 |
Proposed for approval of Shareholders at the Annual General Meeting on 28 July 2025: | ||
Final dividend for 2025 – | 41.2 | 36.3 |
2025 | 2024 | |
Thousands | Thousands | |
Basic weighted average number of shares | 53,581 | 53,776 |
Dilutive potential ordinary shares — share options | 954 | 187 |
54,535 | 53,963 |
Customer | ||||
Goodwill | Trademark | relationships | Total | |
£’m | £’m | £’m | £’m | |
Cost | ||||
At 26 March 2023 | 213.0 | 5.7 | 33.5 | 252.2 |
Acquired on acquisitions | 5.7 | – | 5.0 | 10.7 |
At 30 March 2024 | 218.7 | 5.7 | 38.5 | 262.9 |
Acquired on acquisitions | 2.6 | – | – | 2.6 |
At 29 March 2025 | 221.3 | 5.7 | 38.5 | 265.5 |
Amortisation and impairment | ||||
At 26 March 2023 | – | 2.4 | 26.6 | 29.0 |
Amortisation | – | 1.0 | 4.0 | 5.0 |
Impairment | 15.1 | – | 0.3 | 15.4 |
At 30 March 2024 | 15.1 | 3.4 | 30.9 | 49.4 |
Amortisation | – | 1.2 | 2.4 | 3.6 |
Impairment | – | 0.8 | 0.8 | 1.6 |
At 29 March 2025 | 15.1 | 5.4 | 34.1 | 54.6 |
Net book value | ||||
At 25 March 2023 | 213.0 | 3.3 | 6.9 | 223.2 |
At 30 March 2024 | 203.6 | 2.3 | 7.6 | 213.5 |
At 29 March 2025 | 206.2 | 0.3 | 4.4 | 210.9 |
2025 | 2024 | |
£’m | £’m | |
Fresh Pork | 21.7 | 21.8 |
Livestock* | 26.0 | 23.3 |
Cooked Meats | 90.2 | 90.2 |
Continental Fine Foods | 39.1 | 39.1 |
Premium Cooked Poultry | 9.2 | 9.2 |
Fresh Chicken | 13.7 | 13.7 |
Other | 6.3 | 6.3 |
206.2 | 203.6 |
Budgeted gross | Other operating | Pre-tax discount | |
Cash generating units | margin (£’m) | costs (£’m) | rate (%) |
Fresh Pork and Livestock | (15%) | 21% | 20% |
Cooked Meats | (8%) | 9% | 11% |
Continental Fine Foods | (9%) | 12% | 8% |
Premium Cooked Poultry | (7%) | 9% | 10% |
Fresh Chicken | (15%) | 24% | 19% |
Other | (9%) | 12% | 15% |
Plant, | Assets in the | |||
Freehold land | equipment and | course of | ||
and buildings | vehicles | construction | Total | |
£’m | £’m | £’m | £’m | |
Cost | ||||
At 26 March 2023 | 272.3 | 486.8 | 27. 0 | 786.1 |
Additions | 6.6 | 35.8 | 49.0 | 91.4 |
Acquired on acquisition | 22.7 | 8.0 | – | 30.7 |
Transfers between categories | 7. 4 | 22.1 | (29.5) | – |
Disposals | (0.6) | (21.1) | – | (21.7) |
At 30 March 2024 | 308.4 | 531.6 | 46.5 | 886.5 |
Additions | 15.1 | 26.6 | 95.7 | 137. 4 |
Acquired on acquisition | 17.1 | 3.0 | – | 20.1 |
Transfers between categories | 10.7 | 41.0 | (51.7) | – |
Disposals | (3.5) | (24.4) | – | ( 27.9) |
At 29 March 2025 | 347.8 | 577.8 | 90.5 | 1,016.1 |
Depreciation | ||||
At 26 March 2023 | 50.5 | 271.5 | – | 322.0 |
Charge for the year | 11.0 | 54.5 | – | 65.5 |
Relating to disposals | (0.6) | (19.3) | – | (19.9) |
At 30 March 2024 | 60.9 | 306.7 | – | 3 67.6 |
Charge for the year | 11.6 | 56.5 | – | 6 8.1 |
Relating to disposals | (3.2) | (21.8) | – | (25.0) |
At 29 March 2025 | 69.3 | 341.4 | – | 410.7 |
Net book amounts | ||||
At 25 March 2023 | 221.8 | 215.3 | 27.0 | 464.1 |
At 30 March 2024 | 247. 5 | 224.9 | 46.5 | 518.9 |
At 29 March 2025 | 278.5 | 236.4 | 90.5 | 605.4 |
Land and | Plant, equipment | ||
buildings | and vehicles | Total | |
£’m | £’m | £’m | |
Cost | |||
At 26 March 2023 | 10 7. 5 | 8.8 | 116. 3 |
Acquired on acquisition | 1.4 | – | 1.4 |
Additions | 26.9 | 7.7 | 34.6 |
Disposals | (11.8) | (2.8) | (14.6) |
At 30 March 2024 | 124.0 | 13.7 | 137.7 |
Acquired on acquisition | 4.4 | – | 4.4 |
Additions | 10.2 | 5.1 | 15.3 |
Modifications | 30.1 | – | 30.1 |
Disposals | (4.0) | (3.0) | ( 7. 0) |
At 29 March 2025 | 164.7 | 15.8 | 180.5 |
Depreciation | |||
At 26 March 2023 | 34.7 | 5.3 | 40.0 |
Charge for the year | 13.3 | 2.9 | 16.2 |
Relating to disposals | (8.1) | (2.8) | (10.9) |
At 30 March 2024 | 39.9 | 5.4 | 45.3 |
Charge for the year | 14.5 | 3.7 | 18.2 |
Relating to disposals | (3.7) | (3.0) | (6.7) |
At 29 March 2025 | 50.7 | 6.1 | 56.8 |
Net book amounts | |||
At 25 March 2023 | 72.8 | 3.5 | 76.3 |
At 30 March 2024 | 84.1 | 8.3 | 92.4 |
At 29 March 2025 | 114 .0 | 9.7 | 123.7 |
2025 | 2024 | |
£’m | £’m | |
Lease liabilities: | ||
Current | 16.4 | 17. 3 |
Non-current | 116.3 | 82.1 |
132.7 | 99.4 |
2025 | 2024 | |
£’m | £’m | |
Depreciation charge on right-of-use assets: | ||
Land and buildings | 14.5 | 13.3 |
Plant, equipment and vehicles | 3.7 | 2.9 |
18.2 | 16.2 | |
Interest expense (included in finance costs) | 6.0 | 3.6 |
Provisional fair | |
value | |
£’m | |
Net assets acquired: | |
Property, plant and equipment | 18.6 |
Right-of-use assets | 4.4 |
Biological assets | 6.6 |
Inventories | 0.3 |
Trade and other receivables | 1.9 |
Bank and cash balances | (5.3) |
Trade and other payables | (8.5) |
Income tax payable | (0.3) |
Lease liabilities | (4.4) |
Deferred tax liability | (0.8) |
12.5 | |
Goodwill arising on acquisition | 1.9 |
Total consideration | 14.4 |
Satisfied by: | |
Initial cash consideration | 14.2 |
Deferred consideration | 0.2 |
14.4 | |
Net cash outflow arising on acquisition: | |
Cash consideration paid | 14.2 |
Cash and cash equivalents acquired | 5.3 |
19.5 |
Provisional fair | |
value | |
£’m | |
Net assets acquired: | |
Property, plant and equipment | 1.5 |
Biological assets | 1.3 |
Inventories | 0.1 |
Trade and other receivables | 0.9 |
Bank and cash balances | 0.2 |
Trade and other payables | (0.4) |
Deferred tax liability | (0.3) |
3.3 | |
Goodwill arising on acquisition | 0.7 |
Total consideration | 4.0 |
Satisfied by: | |
Initial cash consideration | 3.8 |
Deferred consideration | 0.2 |
4.0 | |
Net cash outflow arising on acquisition: | |
Cash consideration paid | 3.8 |
Cash and cash equivalents acquired | (0.2) |
3.6 |
Fair value | |
£’m | |
Net assets acquired: | |
Property, plant and equipment | 8.0 |
Right-of-use assets | 1.4 |
Customer relationships | 5.0 |
Trade and other receivables | 0.7 |
Bank and cash balances | 1.6 |
Bank loans | (1.7) |
Trade and other payables | (4.2) |
Lease liabilities | (1.4) |
Provisions | (0.6) |
Deferred tax liability | (1.7) |
7.1 | |
Goodwill arising on acquisition | 2.6 |
Total consideration | 9.7 |
Satisfied by: | |
Initial cash consideration | 9.4 |
Deferred consideration | 0.3 |
9.7 | |
Net cash outflow arising on acquisition: | |
Cash consideration paid | 9.4 |
Cash and cash equivalents acquired | (1.6) |
7.8 |
Fair value | |
£’m | |
Net assets acquired: | |
Property, plant and equipment | 22.7 |
Investment in joint venture | 0.4 |
Biological assets | 7.5 |
Inventories | 1.0 |
Trade and other receivables | 2.3 |
Bank and cash balances | (3.1) |
Bank loans | (4.8) |
Trade and other payables | (16.9) |
Deferred tax liability | (0.6) |
8.5 | |
Goodwill arising on acquisition | 3.1 |
Total consideration | 11.6 |
Satisfied by: | |
Initial cash consideration | 10.5 |
Deferred consideration | 1.1 |
11.6 | |
Net cash outflow arising on acquisition: | |
Cash consideration paid | 11.6 |
Cash and cash equivalents acquired | 3.1 |
14.7 |
2025 | 2024 | |
£’m | £’m | |
Share of net assets | – | 0.8 |
Total interests in joint venture | – | 0.8 |
£’m | |
Investment as at 30 March 2024 | 0.8 |
Revenue | 1.9 |
Interest expense | – |
Income tax expense | – |
Profit for the period | 0.4 |
Group share of profit | 0.2 |
Cash distributions received from joint venture | (0.2) |
Distribution of assets other than cash upon dissolution | (0.8) |
Investment as at 29 March 2025 | – |
Pigs | Chickens | Total | |
£’m | £’m | £’m | |
At 26 March 2023 | 68.6 | 10.5 | 79.1 |
Increase due to purchases | 29.7 | 17.6 | 47. 3 |
Increase due to acquisition | 7. 5 | – | 7. 5 |
Decrease attributable to harvest | (298.5) | (196.8) | (495.3) |
Decreases attributable to sales | (6.8) | (1.5) | (8.3) |
Changes in fair value less estimated costs to sell | 278.6 | 181.2 | 459.8 |
At 30 March 2024 | 79.1 | 11.0 | 9 0.1 |
Increase due to purchases | 23.2 | 18.9 | 42.1 |
Increase due to acquisition | 7.9 | – | 7.9 |
Increase due to dissolution of joint venture | 0.5 | – | 0.5 |
Decrease attributable to harvest | (327.6) | (212.0) | (539.6) |
Decreases attributable to sales | (6.8) | (0.7) | ( 7. 5) |
Changes in fair value less estimated costs to sell | 308.2 | 194.4 | 502.6 |
At 29 March 2025 | 84.5 | 11.6 | 96.1 |
2025 | 2024 | |
£’m | £’m | |
Non-current biological assets: | ||
Pigs | 3.8 | 5.7 |
Chickens | 0.5 | 0.7 |
4.3 | 6.4 | |
Current biological assets: | ||
Pigs | 80.7 | 73.4 |
Chickens | 11.1 | 10.3 |
91.8 | 83.7 |
2025 | 2024 | |
£’m | £’m | |
Net IAS 41 valuation movement on biological assets* | ||
Changes in fair value of biological assets | 502.6 | 459.8 |
Biological assets transferred to cost of sales | (513.7) | (4 57.6) |
(11.1) | 2.2 |
2025 | 2024 | |||
Number | Number | |||
Quantities at year end: | ||||
Breeding sows (Bearer biological assets) | 80,785 | 71,237 | ||
AI Boars | 281 | – | ||
Boars | 1,486 | 1,315 | ||
Pigs (Consumable biological assets) | 912,565 | 755,051 | ||
Breeder chickens (Bearer biological assets) | 472,216 | 441,050 | ||
Broiler chickens (Consumable biological assets) | 5,325,657 | 6 | ,0 | 07, 274 |
Number of pigs produced in the year | 1,797,836 | 1,570,358 | ||
Number of chickens produced in the year | 73,582,499 | 61,985,710 |
2025 | 2024 | |
£’m | £’m | |
Raw materials and work in progress | 76.8 | 70.7 |
Finished goods and goods for resale | 33.6 | 28.1 |
Packaging and consumables | 16.5 | 14.9 |
126.9 | 113.7 |
2025 | 2024 | |
£’m | £’m | |
Financial assets: | ||
Trade receivables | 317.1 | 295.0 |
Other receivables | 23.0 | 15.7 |
340.1 | 310.7 | |
Non-financial assets: | ||
Prepayments | 14.9 | 14.6 |
355.0 | 325.3 |
Trade | Of which: | ||||
receivables | Not due | Past due in the following periods | |||
Less than 30 | Between 30 and | More than 60 | |||
days | 60 days | days | |||
£’m | £’m | £’m | £’m | £’m | |
2025 | 317.1 | 270.6 | 43.5 | 2.4 | 0.6 |
2024 | 295.0 | 255.4 | 3 7. 2 | 1.3 | 1.1 |
£’m | |
Bad debt provision: | |
At 26 March 2023 | 2.5 |
Provided in the year | 0.7 |
Released | (0.4) |
Utilised | (0.1) |
At 30 March 2024 | 2.7 |
Provided in the year | 0.6 |
Released | (0.6) |
Utilised | (0.1) |
At 29 March 2025 | 2.6 |
2025 | 2024 | |
£’m | £’m | |
Current: | ||
Forward currency contracts | 0.3 | – |
0.3 | – |
2025 | 2024 | |
£’m | £’m | |
Current: | ||
Trade payables | 191.4 | 180.0 |
Tax and social security | 15.9 | 11.1 |
Other creditors | 24.1 | 19.8 |
Commercial accruals* | 21.0 | 18.5 |
Other accruals | 75.3 | 80.2 |
Deferred income – Government grants | 0.4 | 0.4 |
328.1 | 310.0 | |
Non-current: | ||
Deferred income — Government grants | 0.5 | 0.9 |
Volume rebates | Advertising and | ||
and similar | marketing | ||
allowances | contributions | Total | |
£’m | £’m | £’m | |
At 25 March 2023 | 10.4 | 2.4 | 12.8 |
Charged to Income Statement | 22.3 | 6.9 | 29.2 |
Paid | (16.8) | (6.7) | (23.5) |
At 30 March 2024 | 15.9 | 2.6 | 18.5 |
Charged to Income Statement | 22.8 | 10.7 | 33.5 |
Paid | (22.5) | (8.5) | (31.0) |
At 29 March 2025 | 16.2 | 4.8 | 21.0 |
2025 | 2024 | |
£’m | £’m | |
Current: | ||
Forward currency contracts | – | 0.2 |
Deferred and contingent consideration (Note 13) | 0.3 | 2.1 |
0.3 | 2.3 | |
Non-current: | ||
Amounts outstanding under revolving credit facility | 46.0 | 28.0 |
Unamortised issue costs | (0.4) | (0.9) |
45.6 | 27.1 |
2025 | 2024 | |
£’m | £’m | |
Movement on hedging instruments: | ||
Gains/(losses) arising in the year | 0.3 | (0.1) |
Reclassification adjustment for gains/(losses) included in the income statement | 0.1 | (0.1) |
0.4 | (0.2) |
2025 | 2024 | |
£’m | £’m | |
In one year or less | – | – |
Between one year and two years | 46.0 | – |
Between two and five years | – | 28.0 |
46.0 | 28.0 | |
Unamortised issue costs | (0.4) | (0.9) |
45.6 | 27.1 |
Lease provisions | Other | Total provisions | |
£’m | £’m | £’m | |
At | 3.6 | 0.8 | 4.4 |
Created | 0.7 | – | 0.7 |
Utilised | (0.7) | (0.1) | (0.8) |
Released | (0.2) | – | (0.2) |
At 29 March 2025 | 3.4 | 0.7 | 4.1 |
2025 | 2024 | |
£’m | £’m | |
Current liabilities | 2.4 | 1.8 |
Non-current liabilities | 1.7 | 2.6 |
4.1 | 4.4 |
Level 1 | Level 2 | Level 3 | Total | |
£’m | £’m | £’m | £’m | |
At 29 March 2025 | ||||
Breeding sows (Bearer biological assets) | – | 6.5 | – | 6.5 |
Boars | – | 0.2 | – | 0.2 |
AI Boars | – | 1.3 | – | 1.3 |
Finished pigs (Consumable biological assets) | – | – | 56.1 | 56.1 |
Sucklers and weaners (Consumable biological assets) | – | – | 20.4 | 20.4 |
Breeder chickens (Bearer biological assets) | – | 2.8 | – | 2.8 |
Eggs | – | 0.7 | – | 0.7 |
Broiler chickens (Consumable biological assets) | – | 8.1 | – | 8.1 |
Total biological assets | – | 19.6 | 76.5 | 96.1 |
Level 1 | Level 2 | Level 3 | ‘Total | |
£’m | £’m | £’m | £’m | |
At 30 March 2024 | ||||
Breeding sows (Bearer biological assets) | – | 12.2 | – | 12.2 |
Boars | – | 0.2 | – | 0.2 |
Finished pigs (Consumable biological assets) | – | – | 49.9 | 49.9 |
Sucklers and weaners (Consumable biological assets) | – | – | 16.9 | 16.9 |
Breeder chickens (Bearer biological assets) | – | 2.2 | – | 2.2 |
Eggs | – | 0.5 | – | 0.5 |
Broiler chickens (Consumable biological assets) | – | 8.2 | – | 8.2 |
Total biological assets | – | 23.3 | 66.8 | 90.1 |
£’m | |
At 30 March 2024 | 66.8 |
Increase due to purchases | 16.6 |
Increase due to acquisition | 5.9 |
Decrease attributable to harvest | (324.5) |
Decreases attributable to sales | (5.1) |
Changes in fair value less estimated costs to sell | 316.8 |
At 29 March 2025 | 76.5 |
2025 | 2024 | |
£’m | £’m | |
Net total (losses)/gains for the period recognised in profit or loss under ‘Change in fair value of biological assets’ | (3.6) | 6.4 |
Net change in unrealised gains for the period recognised in profit or loss attributable to sucklers, weaners and finishers | ||
held at the end of the reporting period | 2.0 | 6.7 |
Fair value | Range of inputs | Relationship of unobservable | ||||
2025 | 2024 | Unobservable | 2025 | 2024 | inputs to fair value | |
Description | £’m | £’m | inputs | £ | £ | |
Suckler price | 49.98 – 51.98 | 51.98 – 55.40 | The higher the market price, | |||
Weaners and sucklers | 20.4 | 16.9 | Weaner price | 58.84 – 61.20 | 56.70 – 64.69 | the higher the fair value. |
Finished pigs | 56.1 | 49.9 | Finisher price | 169.85– 203.58 | 182.83 – 215.19 |
Effect on profit before tax | |||
Increase/decrease in basis points | £’m | ||
2025 | 2024 | ||
Weaners, sucklers and finishers | +1,000 | 3.2 | 2.8 |
-1,000 | (3.2) | (2.8) |
Fixed interest | ||||||
Weighted average effective | At floating | |||||
interest rate | Total | interest rates | 1 year or less | 1–2 years | 2–3 years | |
% | £’m | £’m | £’m | £’m | £’m | |
Financial liabilities: | ||||||
Revolving credit facility | 5.9% | (46.0) | (46.0) | – | – | – |
Financial assets: | ||||||
Cash at bank | 0.0% | 5.9 | 5.9 | – | – | – |
(40.1) | (40.1) | – | – | – |
Fixed interest | ||||||
Weighted average effective | At floating | |||||
interest rate | Total | interest rates | 1 year or less | 1–2 years | 2–3 years | |
% | £’m | £’m | £’m | £’m | £’m | |
Financial liabilities: | ||||||
Revolving credit facility | 6.0% | (28.0) | (28.0) | – | – | – |
Financial assets: | ||||||
Cash at bank | 0.0% | 27.0 | 27.0 | – | – | – |
(1.0) | (1.0) | – | – | – |
2025 | 2024 | |||
Book Value | Fair Value | Book Value | Fair Value | |
£’m | £’m | £’m | £’m | |
Forward currency contracts (asset)/liability (Note 18 and Note 20) | (0.3) | (0.3) | 0.2 | 0.2 |
Contingent consideration (Note 13 and Note 20) | – | – | 1.7 | 1.7 |
Fair Value | ||||
Currency | Amount | Maturities | Exchange rates | £’m |
Euros | €54.6m | 31 Mar 2025 – 01 Dec 2025 | 1.17 – 1.21 | (0.1) |
US Dollar | $8.0m | 7 April 2025 – 25 Jun 2025 | 1.23 – 1.30 | (0.2) |
Increase/ | Effect on profit | |
decrease in basis | before tax | |
points | £’m | |
2025 | ||
Sterling | +10 0 | (0.3) |
-10 0 | 0.3 | |
2024 | ||
Sterling | +10 0 | (0.8) |
-10 0 | 0.8 |
Less than 1 year | 1–2 years | 2–5 years | ‘Over 5 years | Total | |
£m | £m | £m | £m | £m | |
Revolving credit facility | – | 46.0 | – | – | 46.0 |
Deferred and contingent consideration | 0.3 | – | – | – | 0.3 |
Trade and other payables | 328.1 | 0.5 | – | – | 328.6 |
Lease liabilities | 22.5 | 20.9 | 51.9 | 71.4 | 166.7 |
350.9 | 67.4 | 51.9 | 71.4 | 541.6 |
Less than 1 year | 1–2 years | 2–5 years | ‘Over 5 years | Total | |
£m | £m | £m | £m | £m | |
Revolving credit facility | – | – | 28.0 | – | 28.0 |
Deferred and contingent consideration | 2.1 | – | – | – | 2.1 |
Trade and other payables | 310.0 | 0.6 | 0.3 | – | 310.9 |
Derivative Financial Instruments | 0.2 | – | – | – | 0.2 |
Lease liabilities | 19.5 | 18.0 | 42.5 | 34.7 | 114.7 |
331.8 | 18.6 | 70.8 | 34.7 | 455.9 |
2025 | 2024 | 2025 | 2024 | ||
Number | Number | £’m | £’m | ||
At beginning of year | 54,007,610 | 53,702,395 | 5.4 | 5.4 | |
On exercise of share options | 185,762 | 302,549 | – | – | |
Deferred Bonus Plan | – | 2,666 | – | – | |
At end of year | 54,193,372 | 5 4 ,0 | 07,610 | 5.4 | 5.4 |
Number | Exercise price | Exercise period | ||
Savings related | 7,934 | 2,534p | March 2023 – October 2025 | |
Savings related | 25,083 | 2,800p | March 2024 – October 2026 | |
Savings related | 99,980 | 2,899p | March 2025 – October 2027 | |
Savings related | 273,10 | 0 | 2,498p | March 2026 – October 2028 |
LTIP | 7,8 5 0 | Nil | Until July 2033 |
Number of shares | Nominal value of share | Total reserve | ||||
2025 | 2024 | 2025 | 2024 | 2025 | 2024 | |
Number | Number | £ | £ | £’m | £’m | |
At beginning of year | 400,250 | – | 40,025 | – | 15.6 | – |
Shares acquired by Employee Benefit Trust | 524,250 | 400,250 | 52,425 | 40,025 | 25.3 | 15.6 |
Transferred to beneficiaries of the share award schemes | (148,935) | – | (14,894) | – | (5.5) | – |
At end of year | 775,565 | 400,250 | 77,556 | 40,025 | 35.4 | 15.6 |
2025 | 2025 | 2024 | 2024 | |
Number | WAEP (£) | Number | WAEP (£) | |
Outstanding at beginning of year | 758,538 | – | 695,658 | – |
Granted during the year (i) | 248,272 | – | 286,295 | – |
Lapsed during the year | (35,052) | – | (84,867) | – |
Exercised during the year (ii) | (153,104) | – | (138,548) | – |
Outstanding at end of year (iii) | 818,654 | – | 758,538 | – |
Exercisable at end of year | 18,494 | – | 11,749 | – |
2025 | 2025 | 2024 | 2024 | |
Number | WAEP (£) | Number | WAEP (£) | |
Outstanding at beginning of year | 893,923 | 28.08 | 898,138 | 26.58 |
Granted during the year (i) | 311,367 | 39.78 | 288,842 | 31.27 |
Lapsed during the year | (86,409) | 29.93 | (127,815) | 26.79 |
Exercised during the year (ii) | (167,450) | 27.82 | (165,242) | 26.50 |
Outstanding at end of year (iii) | 951,431 | 31.78 | 893,923 | 28.08 |
Exercisable at end of year | 92,957 | 28.67 | 75,991 | 27.27 |
Measures | 2025 | LTIP | 2025 | SAYE | 2024 | LTIP | 2024 | SAYE |
Dividend yield | 0.00% | 1.90% | 2.35% | 2.14% | ||||
Expected share price volatility | 19.02% | –20.90% | 20.20% | –23.78% | 22.65%–22.93% | 22.25%–25.35% | ||
Risk-free interest rate | 3.64%–3. | 97% | 4.21%–4.35% | 4.67%–5.05% | 3.32%–3. | 53% | ||
Expected life of option | 3 years | 3.44–5.44 years | 3 years | 3.42–5.42 years | ||||
Exercise prices | £nil | £39.78 | £nil | £31.27 |
2025 | 2024 | |
a) Change in benefit obligation | £’m | £’m |
Benefit obligation at the beginning of the year | 20.8 | 22.1 |
Interest cost | 1.0 | 1.0 |
Remeasurement (gains)/losses: | ||
Actuarial gains arising from changes in financial assumptions | (3.1) | (1.8) |
Other experience items | – | 0.2 |
Benefits paid from plan | (0.9) | (0.7) |
Benefit obligation at the end of the year | 17.8 | 20.8 |
2025 | 2024 | |
b) Change in plan assets | £’m | £’m |
Fair value of plan assets at the beginning of the year | 21.0 | 22.3 |
Interest income | 1.0 | 1.0 |
Return on plan assets | (3.3) | (1.6) |
Employer contributions | – | – |
Benefits paid from the plan | (0.9) | (0.7) |
Fair value of plan assets at end of year | 17.8 | 21.0 |
2025 | 2024 | |
c )Amounts recognised in the balance sheet | £’m | £’m |
Present value of funded obligations | (17.8) | (20.8) |
Fair value of plan assets | 17.8 | 21.0 |
Net asset recorded in the balance sheet | – | 0.2 |
2025 | 2024 | |
d) Components of pension cost | £’m | £’m |
Amounts recognised in the income statement: | ||
Interest cost | 1.0 | 1.0 |
Expected return on plan assets | (1.0) | (1.0) |
Total pension cost recognised in the income statement | – | – |
Actual return on assets | ||
Actual return on plan assets | (2.3) | (0.6) |
Amounts recognised in the Group statement of comprehensive income | ||
Actuarial (losses)/gains immediately recognised | (0.2) | – |
e) Principal actuarial assumptions | 2025 | 2024 |
Discount rate | 5.75% | 4.85% |
Rate of price inflation | 3.05% | 3.15% |
Revaluation of deferred pensions: | ||
Benefits accrued prior to 1 January 1998 | 5.00% | 5.00% |
Benefits accrued after 1 January 1998 | 3.05% | 3.15% |
Rate of compensation increase: | ||
Benefits accrued prior to 1 January 1997 | 3.00% | 3.00% |
Benefits accrued after 1 January 1997 | 3.05% | 3.15% |
Future expected lifetime of pensioner at age 65: | 2025 | 2024 |
Current pensioners: | ||
Male | 20.9 | 20.9 |
Female | 23.8 | 23.8 |
Future pensioners: | ||
Male | 22.2 | 22.2 |
Female | 25.2 | 25.2 |
2025 | 2024 | |
£’m | £’m | |
Deferred pensioners | 10.7 | 12.3 |
Pensions in payment | 7.1 | 8.5 |
17.8 | 20.8 |
2025 | 2024 | |
Fair value of | Fair value of | |
plan assets | plan assets | |
f) Plan assets | £’m | £’m |
Annuities | 1.4 | 1.8 |
Cash | 0.3 | 0.5 |
Buy-in policy | 16.1 | 18.7 |
Total | 17.8 | 21.0 |
At 30 March | Acquired on | Other non-cash | At 29 March | ||
2024 | acquisition | Cashflow | changes | 2025 | |
£’m | £’m | £’m | £’m | £’m | |
Cash and cash equivalents | 27.0 | (5.1) | (16.0) | – | 5.9 |
Revolving credit facility | (2 7.1) | – | (18.0) | (0.5) | (45.6) |
Lease liabilities | (99.3) | (4.4) | 22.2 | (51.2) | (132.7) |
Net debt | (99.4) | (9.5) | (11.8) | (51.7) | (172.4) |
At 25 March | Acquired on | Other non-cash | At 30 March | ||
2023 | acquisition | Cashflow | changes | 2024 | |
£’m | £’m | £’m | £’m | £’m | |
Cash and cash equivalents | 20.3 | (1.5) | 8.2 | – | 27.0 |
Bank loans | – | (6.5) | 6.5 | – | – |
Revolving credit facility | (40.5) | – | 14.0 | (0.6) | ( 27.1) |
Lease liabilities | (81.2) | – | 17.8 | (35.9) | (99.3) |
Net debt | (101.4) | (8.0) | 46.5 | (36.5) | (99.4) |
2025 | 2024 | |
£’m | £’m | |
Not later than one year | 0.1 | 0.2 |
After one year but not more than five years | – | – |
After five years | – | – |
0.1 | 0.2 |
2025 | 2024 | |
£’m | £’m | |
Short-term employee benefits | 9.7 | 8.2 |
Share-based payments | 3.2 | 3.6 |
12.9 | 11.8 |
2025 | 2024 | ||
£’m | £’m | Change | |
Revenue | 2,723.3 | 2,599.3 | +4.8% |
Elsham Linc Limited | (0.6) | – | |
Froch Foods Limited | (5.5) | – | |
J.S.R. Genetics Limited and JSR Pyramid Limited | (3.8) | – | |
Piggy Green Limited and Fornham Pigs Limited | (0.2) | – | |
Like-for-like revenue | 2,713.2 | 2,599.3 | +4.4% |
2025 | 2024 | ||
£’m | £’m | Change | |
Gross profit | 408.8 | 376.9 | +8.5% |
Net IAS41 valuation movement | 11.1 | (2.2) | |
Adjusted gross profit | 419.9 | 374.7 | +12.1% |
2025 | 2024 | ||
£’m | £’m | Change | |
Group operating profit | 190.6 | 166.9 | +14 . 2 % |
Net IAS41 valuation movement | 11.1 | (2.2) | |
Amortisation of intangible assets | 3.6 | 5.0 | |
Impairment of intangible assets | 1.6 | 15.4 | |
Adjusted Group operating profit | 206.9 | 185.1 | +11. 8 % |
Depreciation of property, plant and equipment | 68.1 | 65.5 | |
Depreciation of right-of-use assets | 18.2 | 16.2 | |
Adjusted EBITDA | 293.2 | 266.8 | +9.9% |
2025 | 2024 | ||
£’m | £’m | Change | |
Profit before tax | 181.6 | 158.4 | +14 . 6% |
Net IAS41 valuation movement | 11.1 | (2.2) | |
Amortisation of intangible assets | 3.6 | 5.0 | |
Impairment of intangible assets | 1.6 | 15.4 | |
Adjusted profit before tax | 197.9 | 176.6 | +12 .1% |
2025 | 2025 | 2024 | 2024 | |||
2025 | Basic | Diluted | 2024 | Basic | Diluted | |
£’m | pence | pence | £’m | pence | pence | |
On profit for the year | 134.3 | 250.5 | 246.1 | 113.1 | 210.4 | 209.7 |
Amortisation of intangible assets | 3.6 | 6.8 | 6.7 | 5.0 | 9.4 | 9.3 |
Tax on amortisation of intangible assets | (0.9) | (1.7) | (1.7) | (1.3) | (2.3) | (2.3) |
Net IAS 41 valuation movement | 11.1 | 20.8 | 20.4 | (2.2) | (4.2) | (4.1) |
Tax on net IAS 41 valuation movement | (2.8) | (5.2) | (5.1) | 0.6 | 1.0 | 1.0 |
Impairment of goodwill | – | – | – | 15.1 | 28.0 | 27.9 |
Impairment of intangible assets | 1.6 | 3.0 | 3.0 | 0.3 | 0.6 | 0.6 |
Tax on impairment of intangible assets | (0.4) | (0.8) | (0.8) | (0.1) | (0.1) | (0.1) |
On adjusted profit for the year | 146.5 | 273.4 | 268.6 | 130.5 | 242.8 | 242.0 |
2025 | 2024 | ||
£’m | £’m | Change | |
Net cash from operating activities | 216.3 | 228.4 | −5.3% |
Net interest paid | (2.7) | (5.0) | |
Free cash flow | 213.6 | 223.4 | -4.4% |
2025 | 2024 | ||
£’m | £’m | Change | |
Free cash flow | 213.6 | 223.4 | -4.4% |
Non-growth capital expenditure | (31.4) | (2 2.1) | |
Net IAS 41 valuation movement | (11.1) | 2.2 | |
Lease capital paid | (16.2) | (14.2) | |
Lease interest paid | (6.0) | (3.6) | |
148.9 | 185.7 | ||
Adjusted profit for the year | 146.5 | 130.5 | |
Free cash conversion | 101.6% | 142.3% | -4,066 bps |
2025 | 2024 | ||
£’m | £’m | Change | |
Average opening and closing net assets | 949.7 | 87 7. 2 | |
Average opening and closing net debt | 135.9 | 100.4 | |
Average opening and closing pension surplus | (0.1) | (0.2) | |
Average opening and closing deferred tax | 30.2 | 24.6 | |
1,115.7 | 1,002.0 | ||
Adjusted Group operating profit | 206.9 | 18 5.1 | |
Return on capital employed | 18.5% | 18.5% | +7 bps |